The other question is given Neuren’s drug was recently approved...

The other question is given Neuren’s drug was recently approved my main question is given Neuren has been granted ODD for the Rett syndrome does this give them 7 year marketing exclusivity or not? The FDA approval for Daybue didn’t mention exclusivity granted for their drug (they got paediatric rare drug PRV) so I am guessing we can also stand to get marketing approval if we fly past phase 3.

https://data-api.marketindex.com.au/api/v1/announcements/XASX:NEU:2A1436933/pdf/inline/fda-approves-daybue-the-first-treatment-for-rett-syndrome